Bristol-Myers Squibb, Drug Prices & Medicare Spending

Bristol-Myers Squibb manufactures 20 drugs tracked by Medicare Part D with total spending of $39.5B.

Drugs Tracked

$39.5B

Medicare Spending

$758.43

Avg Cost/Claim

90%

Have Generics

Bristol-Myers Squibb Drugs, Ranked by Medicare Spending

#	Drug	Generic Name	Cost/Claim	Medicare Spending	YoY Change	Generic?
1	Eliquis	Apixaban	$510.00	$16.6B	+14.2%	Yes
2	Revlimid	Lenalidomide	$12,786.00	$7.8B	-3.4%	No
3	Opdivo	Nivolumab	$15,821.00	$5.1B	+15.8%	Yes
4	Pomalyst	Pomalidomide	$17,250.00	$3.3B	+4.7%	No
5	Orencia	Abatacept	$3,546.00	$1.2B	-4.2%	Yes
6	Yervoy	Ipilimumab	$13,058.00	$1.1B	+8.9%	Yes
7	Sprycel	Dasatinib	$7,065.00	$876.0M	-6.7%	Yes
8	Reblozyl	Luspatercept	$6,593.00	$567.0M	+42.4%	Yes
9	Opdualag	Nivolumab/Relatlimab	$13,500.00	$567.0M	+86.4%	Yes
10	Zeposia	Ozanimod	$6,706.00	$456.0M	+32.4%	Yes
11	Vidaza	Azacitidine	$9,583.00	$345.0M	-8.4%	Yes
12	Thalomid	Thalidomide	$13,000.00	$234.0M	-18.6%	Yes
13	Inrebic	Fedratinib	$16,714.00	$234.0M	+12.3%	Yes
14	Sotyktu	Deucravacitinib	$3,441.00	$234.0M	0.0%	Yes
15	Nulojix	Belatacept	$2,721.00	$234.0M	+8.6%	Yes
16	Baraclude	Entecavir	$1,435.00	$178.0M	-18.6%	Yes
17	Pravastatin	Pravastatin Sodium	$10.00	$89.0M	-28.4%	Yes
18	Warfarin	Warfarin Sodium	$10.00	$89.0M	-32.4%	Yes
19	Idhifa	Enasidenib	$14,833.00	$89.0M	-12.4%	Yes
20	Sustiva	Efavirenz	$1,854.00	$89.0M	-32.4%	Yes

Frequently Asked Questions

Bristol-Myers Squibb manufactures 20 drugs tracked by Medicare Part D, with total annual spending of $39.5B.

Pomalyst (Pomalidomide) is the most expensive at $17,250.00 per claim.

18 of 20 Bristol-Myers Squibb drugs (90%) have generic alternatives available. Generic drugs can save patients 30-80% compared to brand-name versions.

this entity is one of the data points covered by this site’s U.S. Medicare prescription-drug pricing dataset. The detail above comes directly from CMS Medicare Part D Drug Spending data; the context that follows situates the headline numbers against the broader distribution across U.S. prescription drugs.

Every number on this page links back to CMS Medicare Part D Drug Spending data; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.

For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within U.S. prescription drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.

Source: CMS Medicare Part D Spending, 2026.